Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director | April 01, 2024 | April 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date April 01, 2024 · Filed April 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,075 |
Reported balance
After 2024-04-01 transaction · row 1
1 source rowRow 1 · 2024-04-01 · Grant · Acquired 1,358 · Balance 22,075 F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy DF Investment Partners LLC | 770,607 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 770,607 F3: Shares held directly by DF Investment Partners LLC ("DFIP"). The Reporting Person serves as managing member of DFIP and may be deemed to exercise voting and investment power over the shares held by DFIP. The Reporting Person disclaims beneficial ownership of the shares held by DFIP except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy G&E Dubin Family Foundation | 20,000 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 20,000 F4: Shares held directly by G&E Dubin Family Foundation. The Reporting Person may be deemed to exercise voting and investment power over the shares held by G&E Dubin Family Foundation and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2024.
F3: Shares held directly by DF Investment Partners LLC ("DFIP"). The Reporting Person serves as managing member of DFIP and may be deemed to exercise voting and investment power over the shares held by DFIP. The Reporting Person disclaims beneficial ownership of the shares held by DFIP except to the extent of his pecuniary interest therein.
F4: Shares held directly by G&E Dubin Family Foundation. The Reporting Person may be deemed to exercise voting and investment power over the shares held by G&E Dubin Family Foundation and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2024 Filed Apr 2, 2024 16:34 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,358 | $8.10 | $10,999.80 |
DisclosureSEC source: 0001662579-24-000037 · wk-form4_1712090040.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,075 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2024. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 16:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,687 | $6.52 | $10,999.24 |
DisclosureSEC source: 0001662579-24-000006 · wk-form4_1704316341.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,717 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2024. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 16:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 6,470 | $1.70 | $10,999.00 |
DisclosureSEC source: 0001662579-23-000108 · wk-form4_1696364836.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,030 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 2, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 16:24 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 3,887 | $2.83 | $11,000.21 |
DisclosureSEC source: 0001662579-23-000067 · wk-form4_1688588669.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,560 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 3, 2023. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000059 · wk-form4_1686947027.xml · derivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 16:20 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 3,438 | $3.20 | $11,001.60 |
DisclosureSEC source: 0001662579-23-000046 · wf-form4_168063957956687.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,673 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 16:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,725 | $6.38 | $11,005.50 |
DisclosureSEC source: 0001662579-23-000004 · wf-form4_167286693048091.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,235 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 3, 2023. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 18:06 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,265 | $8.69 | $10,992.85 |
DisclosureSEC source: 0001662579-22-000005 · wf-form4_166492113147782.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,510 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 3, 2022. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 16:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,372 | $8.03 | $11,017.16 |
DisclosureSEC source: 0001209191-22-040603 · doc4.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,245 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2022. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 16:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001209191-22-038864 · doc4.xml · derivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 16:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 379 | $26.46 | $10,028.34 |
DisclosureSEC source: 0001209191-22-023021 · doc4.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 873 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 4, 2022. Read SEC document |
| January 04, 2022 Filed Jan 18, 2022 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 199 | $31.58 | $6,284.42 |
DisclosureSEC source: 0001209191-22-003502 · doc4.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 4, 2022. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 16:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 138 | $44.99 | $6,208.62 |
DisclosureSEC source: 0001209191-21-059526 · doc4.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 4, 2021. Read SEC document |
| July 02, 2021 Filed Aug 20, 2021 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 157 | $39.72 | $6,236.04 |
DisclosureSEC source: 0001209191-21-052780 · doc4.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 2, 2021. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $44.64 | $0.00 |
DisclosureSEC source: 0001209191-21-020777 · doc4.xml · derivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2031-03-11 F1 · derivative.exercise_date: One-third of this option shall vest and become exercisable on March 12, 2022, with the remainder vesting in eight equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.